COMMUNIQUÉS West-GlobeNewswire

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024

06/05/2024 - 18:03

Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans for a registrational [...]

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06/05/2024 - 18:00

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]

Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

06/05/2024 - 18:00

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]

Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD

06/05/2024 - 18:00

` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET , Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based [...]

Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024

06/05/2024 - 17:46

Press Release Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 Shareholders adopted all resolutions proposed by the Board of Directors at the Ordinary and Extraordinary General Meetings May 6, [...]

Nicox : assemblée générale ordinaire et extraordinaire du 6 mai 2024

06/05/2024 - 17:46

Communiqué de presse Nicox : assemblée générale ordinaire et extraordinaire du 6 mai 2024 Les actionnaires ont adopté toutes les résolutions à titre ordinaire et à titre extraordinaire agréées par le Conseil d’ [...]

Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

06/05/2024 - 17:16

Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events reported and [...]

IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024

06/05/2024 - 17:00

LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces [...]

Transactions in Connection with Share Buy-back Program

06/05/2024 - 16:01

Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The [...]

Survey: Nurses See Little Improvement in 2024

06/05/2024 - 16:00

Over One-Third Extremely Likely to Change Jobs DALLAS, May 06, 2024 (GLOBE NEWSWIRE) -- The majority of nurses (80%) think 2024 will be either no better or worse for nurses than 2023, according to a new survey by AMN [...]

Safety Shot Provides Shareholder Update Highlighting Significant Milestones and Progress

06/05/2024 - 15:08

JUPITER, FL, May 06, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (The “Company” or “Safety Shot”) today released a shareholder update to highlight the Company’s progress and strategic vision to maximize [...]

Stride Autism Centers Opens New Facility in Oak Park to Improve Autism Services in Illinois

06/05/2024 - 15:00

OAK PARK, Ill., May 06, 2024 (GLOBE NEWSWIRE) -- Stride Autism Centers ("Stride"), renowned for its mission-driven, evidence-based therapy for children with autism, announces the opening of its innovative new center in [...]

Inmagene Reports Positive Interim Results from Phase 2a Trial of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Atopic Dermatitis

06/05/2024 - 15:00

Treatment with IMG-007, the only clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb), led to rapid, marked, and durable improvement of skin signs in patients with atopic dermatitis (AD). Overall, IMG-007 was [...]

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13

06/05/2024 - 15:00

Company to Host Conference Call, May 13, 2024 at 4:30 p.m. ET SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based [...]

Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®)

06/05/2024 - 15:00

-- The Centers for Medicare & Medicaid Services (CMS) released its preliminary Medicare payment determinations for the PoNS Controller and Mouthpiece -- -- Public Meeting Scheduled for May 29, 2024 -- NEWTOWN, Pa., [...]

Nova Leap Health Corp. Re-engages Acquisition Program with Closing of Strategic Acquisition in Massachusetts

06/05/2024 - 14:40

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 06, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) ("Nova Leap" or “the Company”), a [...]

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

06/05/2024 - 14:30

- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone - Effect seen across both Panc02 and KPC [...]

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

06/05/2024 - 14:30

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® ( [...]

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

06/05/2024 - 14:30

Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage [...]